Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

NCT03976323 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1003

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Nonsquamous Non-small-cell Lung

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Olaparib

Sponsor

Merck Sharp & Dohme LLC